GLYCOEXPRESS
LIVE

Serial Number

79068784

Owner

Glycotope GmbH

Attorney

GARY D. KRUGMAN

Filing Date

Nov 27, 2008

Add to watchlist:

No watchlists yet
View on USPTO

GLYCOEXPRESS Trademark

Serial Number: 79068784 • Registration: 3991708

GLYCOEXPRESS is a trademark filed by Glycotope GmbH on November 27, 2008. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Glycotope GmbH (13 trademarks)

Robert-Rössle-Str. 10

Entity Type: 99

Trademark Details

Filing Date

November 27, 2008

Registration Date

July 12, 2011

Published for Opposition

April 26, 2011

Cancellation Date

January 28, 2022

Goods & Services

[Pharmaceutical and veterinary preparations for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; sanitary preparations for medical purposes; dietetic foods adapted for medical use; food for babies; medical plasters; materials for medical dressings; disinfectants for sanitary purposes; preparations for destroying vermin; fungicides, herbicides; adjuvants for medical purposes; medicines for human and veterinary purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; biological preparations for medical purposes; dietetic food adapted for medical purposes; enzyme, proteins, antibodies, cells, microorganisms as well as fragments, fractions, elements and lysates thereof for medical purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine, and as nutritional additives for medical purposes for use in foods and dietary supplements for human consumption; vaccines; carbohydrates for medical purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; cultures of microorganisms for medical or veterinary purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; cultures of human cells for medical or veterinary purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; medical drinks for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; microorganisms, cells and preparations containing elements, fragments, fractions and lysates of microorganisms or cells for medical and veterinary purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; biological therapeutics, namely, therapeutics containing cells, microorganisms, proteins, glycoproteins, peptides, glycopeptides or modified or conjugated versions thereof for use in the prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; milk ferments for pharmaceutical purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; nutritional additives and nutritional supplement additives for medical purposes for use in foods and dietary supplements for human consumption; nutrients for medical purposes for human or animals, namely, nutritional additives in the nature of enzymes, proteins, antibodies, cells, microorganisms as well as fragments, fractions, elements and lysates thereof; sugar and carbohydrates for medical purposes, namely, therapeutically and prophylactically active sugar and carbohydrates, dietetic sugar and carbohydrates, sugar and carbohydrate replacements]

[Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry, except fungicides, herbicides, insecticides and parasiticides; unprocessed artificial resins; unprocessed plastics; fertilizing preparations; fire extinguishing compositions; tempering and soldering chemicals; chemical substances for fermenting and preserving food stuffs; tanning agents for use in the manufacture of leather; adhesives used in industry; bacteria and cell preparations and elements, fragments, fractions and lysates thereof, except for medical or veterinary purposes, namely, for use in protein production, food manufacturing, scientific research, waste water treatment, bacteria and cell preparations for use in expression of engineered or glycosylated proteins and peptides; preparations containing bacteria and cells, except for medical or veterinary purposes, namely, for use in protein production, food manufacturing, scientific research, waste water treatment; biological preparations for laboratories, except for medical or veterinary purposes, namely, for use in bacterial and cell engineering, cultivation, harvesting, protein production; chemical preparations for analysis in laboratories, namely, preparations for protein, peptide, engineered proteins and peptides, glycoproteins, glycosylation, antibody or antigen analysis, preparations comprising antibody reagents used for the detection of antigens; chemical preparations for scientific purposes; chemical reagents except for medical or veterinary purposes and biological reagents in the nature of reagents for use in protein production, bacterial and cell engineering, cultivation and harvesting, probes for detecting and analyzing molecules in protein or nucleotide arrays, except for medical or veterinary purposes; diagnostic preparations, except for medical or veterinary purposes; enzymes, proteins and respective preparations for industrial purposes, namely, engineered proteins, glycosylated proteins, antibodies, enzymes for use in glycosylation, enzyme substrates, proteins used in the manufacture of cosmetics, beverages, food products and food supplements; ferments for chemical purposes, namely, yeast, bacterium, mold, or enzyme, that causes fermentation; in-vitro diagnostic preparations, other than for medical purposes; carbohydrates used as an ingredient or as an integral component in food or nutraceuticals; cultures of microorganisms and cells and elements, fragments, fractions and lysates thereof, other than for medical or veterinary purposes, namely, cultures of microorganisms and cells other than for medical and veterinary use, microorganism or cell cultures for use in protein production, food manufacturing, scientific research, waste water treatment, cultures of microorganisms or cells for use in expression of glycosylated proteins and peptides; gene expression systems for proteins and peptides, particularly on the basis of cells, particularly human cells and microorganisms, namely, gene expression systems comprising biochemicals, assays, and reagents for use in manufacturing engineered or glycosylated proteins or peptides and for scientific research, gene expression systems comprising biochemicals, assays and reagents with optimized glycosylation activity for use in manufacturing proteins or peptides, in particular engineered or glycosylated proteins or peptides, and for scientific research; milk ferments for medical research purposes]

Scientific and technological services, namely, [bacteria and] cell engineering services, [bacteria and] cell cultivation and harvesting services, research and development related to protein production, glycosylation, optimization of protein, antibody and enzyme activity, [bacteria and] cell engineering, cultivation and harvesting; research and design services in the field of biotechnology, protein production, glycosylation, optimization of protein, antibody and enzyme activity, [bacteria and] cell engineering, cultivation and harvesting; industrial analysis and research services in the field of biotechnology, protein production, glycosylation, protein, antibody and enzyme activity, [bacteria and] cell engineering, cultivation and harvesting; [design and development of computer hardware and software;] biological research; services of a [chemical or] biological laboratory; [technical surveys, namely, conducting biotechnology surveys, pharmacology surveys; conducting scientific surveys in the field of biotechnology, bacterial and cell engineering, protein production, glycosylation;] research and development in the field of [bacteriology, ]cytology, antibody technology, [chemistry, immunology, cosmetics of expression systems in the nature of glycosylation of proteins, peptides, antibodies and enzymes, particularly for proteins and peptides; quality control;] research and development of new products and technologies in the field of biotechnology, protein production, glycosylation, protein, antibody and enzyme activity,[ bacteria and] cell engineering, cultivation and harvesting for others; technology and scientific consultancy in the field of biotechnology, protein production, glycosylation, protein, antibody and enzyme activity, [bacteria and] cell engineering, cultivation and harvesting; research and development in the field of glycomics, expression systems in the nature of glycosylation of proteins, peptides, antibodies and enzymes, development and improvement of cells, cell lines [and microorganisms,] antibody-engineering, optimized biological therapeutics; [nutraceuticals, and food and nutritional supplements;] research, [quality control,] technology consultancy and product development in the field of proteins, antibodies, [microorganisms] and cells; research and development in the field of [microorganisms and] cells

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Nov 6, 2022 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Oct 6, 2022 INTS
INVALIDATION PROCESSED
Oct 6, 2022 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Sep 28, 2022 INTR
CANCELLED SECTION 71
Jan 28, 2022 C71T
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Jul 12, 2020 REM4
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 16, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 16, 2019 REAP
INTERNATIONAL REGISTRATION RENEWED
Dec 27, 2018 RNWL
PARTIAL INVALIDATION PROCESSED BY THE IB
Oct 19, 2018 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sep 13, 2018 INPS
INVALIDATION PROCESSED
Sep 13, 2018 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Sep 3, 2018 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Jul 27, 2017 NA75
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Jul 27, 2017 C75P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jul 22, 2017 APRE
TEAS SECTION 71 & 15 RECEIVED
Jul 6, 2017 ES75
NEW REPRESENTATIVE AT IB RECEIVED
Dec 14, 2013 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 3, 2013 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jan 6, 2012 FICS
FINAL DISPOSITION PROCESSED
Jan 5, 2012 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 12, 2011 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 12, 2011 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 26, 2011 NPUB
PUBLISHED FOR OPPOSITION
Apr 26, 2011 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 23, 2011 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 6, 2011 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 6, 2011 OP2R
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 22, 2011 PREV
EXPARTE APPEAL TERMINATED
Mar 22, 2011 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 21, 2011 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 21, 2011 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 21, 2011 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 21, 2011 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 21, 2011 CNEA
NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Mar 11, 2011 GEA1
ACTION DENYING REQ FOR RECON E-MAILED
Mar 11, 2011 GECD
ACTION CONTINUING FINAL - COMPLETED
Mar 11, 2011 CNCF
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 5, 2011 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 17, 2011 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 17, 2011 OPNR
EX PARTE APPEAL-INSTITUTED
Feb 14, 2011 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Feb 14, 2011 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Feb 14, 2011 EXAF
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 2, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 2, 2011 CRFA
ASSIGNED TO LIE
Jan 31, 2011 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jan 31, 2011 ERFR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 28, 2010 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 28, 2010 REAP
FINAL REFUSAL MAILED
Aug 12, 2010 CNFR
FINAL REFUSAL WRITTEN
Aug 11, 2010 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 27, 2010 TEME
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Jan 21, 2010 LIMN
LIMITATION OF GOODS RECEIVED FROM IB
Jan 21, 2010 LIMG
LIMITATION OF GOODS/SERVICES FROM IB ENTERED
Jan 5, 2010 LIMS
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 22, 2009 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 22, 2009 TROA
LIMITATION OF GOODS RECEIVED FROM IB
Nov 30, 2009 LIMG
ATTORNEY REVIEW COMPLETED
Oct 17, 2009 ATRV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
Sep 25, 2009 CREV
REFUSAL PROCESSED BY IB
Sep 19, 2009 RFNP
CORRECTION TRANSACTION RECEIVED FROM IB
Sep 18, 2009 CRCV
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 26, 2009 RFCS
REFUSAL PROCESSED BY MPU
Jun 26, 2009 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 26, 2009 RFCR
NON-FINAL ACTION WRITTEN
Jun 25, 2009 CNRT
APPLICATION FILING RECEIPT MAILED
Jun 23, 2009 MAFR
ASSIGNED TO EXAMINER
Jun 19, 2009 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 19, 2009 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 18, 2009 REPR